Higher ADI was significantly associated with lower MMSE score. 5 key findings →
Design: cross-sectional Participants: 469 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
analysis of returning home at discharge included 87,797 patients; 57,104 (65%) were discharged home. 5 key findings →
Participants: 87,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this analytic cohort of 4130 participants, 486 (11.8%) experienced at least one hospitalization with delirium. 5 key findings →
Design: prospective cohort Participants: 4,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
In 7989 cognitively unimpaired participants (median [range] age, 54 [30-90] years; 4877 [61.3%] female; mean [SD] BMI, 25.9 [4.2]; mean [SD] eGFR, 80.7 [14.7] mL/min/1.73 m2), older age, lower BMI, and reduced kidney function were associated with increased NfL and GFAP concentrations; female sex was associated with increased GFAP concentrations. 5 key findings →
Design: cross-sectional Participants: 179 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
< 0.001). Stage-specific tau-PET region-of-interest selection reduced required sample sizes by 30%-93% for detecting hypothetical disease-modifying drug effects. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
AD exhibited elevated serum GFAP levels in comparison to control patients (P < 0.0001). 5 key findings →
Participants: 1,273 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
CSF SDC4 levels were elevated in AD, including the earliest preclinical stages, compared to controls and were closely associated with CSF and imaging biomarkers of amyloid and tau, and CSF biomarkers of neuronal and synaptic injury, astrocytic reactivity and microglial dysregulation. 1 key finding →
Design: cross-sectional Participants: 1,041 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study included 560 amyloid-positive participants (BioFINDER: n = 431; mean [SD] age, 73.6 [7.0] years; 212 female [49.2%] and 219 male [51.8%]; TRIAD: n = 129; mean [SD] age, 70.4 [8.3] years; 76 female [58.9%] and 53 male [41.1%]). 5 key findings →
Design: cohort study Participants: 431 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 503 participants (mean [SD] age, 64.6 [2.8] years; 321 [63.8%] women; 305 [60.6%] Hispanic, 120 [23.9%] non-Hispanic Black, and 78 [15.5%] non-Hispanic White) with Aβ PET, MRI (n = 501), and tau PET (n = 355) data were studied. 5 key findings →
Design: cross-sectional Participants: 501 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ObjectivesEmerging evidence suggests that the genetic architecture of Alzheimer disease (AD) and Parkinson disease (PD) risk varies across ancestries. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The study included 1,028 participants (mean age at baseline 76.4 years; 47.6% female): 521 with ADP, 96 with LBP, and 411 with mixed AD-LBP. 5 key findings →
Design: cohort study Participants: 1,028 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants with more FTUs were found to have a slower biological ageing process. 5 key findings →
Participants: 22,900 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global rise in dementia necessitates scalable cognitive assessments that can evolve to serve both clinical and research applications. 5 key findings →
Participants: 1,664 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Up-to-date, strictly cross-nationally comparable and nationally representative data on cognitive health are essential for our understanding of the dementia-related challenges in healthcare, to detect shortcomings in healthcare systems and to design effective prevention strategies. 1 key finding →
Participants: 47,773 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Forty-three proteins were differentially regulated in FTD compared to controls and AD, reflecting axon development, regulation of synapse assembly, and cell-cell adhesion mediator activity pathways. 5 key findings →
Participants: 189 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive status was determined for 5414 participants, with a dementia prevalence of 8.9% when assessed at a mean age of 81 years. 3 key findings →
Design: cohort study Participants: 5,414 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 2176 person living with dementia-caregiver dyads were enrolled; 1271 persons living with dementia (58.4%) and 1650 caregivers (75.8%) were female, and their mean (SD) age were 80.6 (8.5) years and 65.2 (12.3) years, respectively. 5 key findings →
Participants: 1,271 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
From an initial cohort of 18 605 participants, 10 058 were included (5062 men [50.3%]; 4996 women [49.7%]; mean [SD] age, 60.9 [7.2] years). 5 key findings →
Design: cohort study Participants: 605 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 1869 participants contributed 5309 observations (mean age 82.9 years, 21.0% Black, 9.3% met research-based dementia criteria). 5 key findings →
Participants: 1,869 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
. Longitudinally, older age (OR=1.14 [1.06-1.22], p<.001), higher levels of p-tau217 (OR=10.37 [3.00-35.02], p<.001) and higher neuropsychiatric symptoms (OR=1.19 [1.02-1.39], p=.023) were associated with higher odds of progression to dementia. 5 key findings →
Design: cross-sectional Participants: 104 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 9,361 SPRINT participants (mean age 67.1 ± 9.5 years, 36.7% female, 58.7% non-Hispanic White), 710 and 1,289 were new users of an ARB or ACEI. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Individuals with dementia and their care partners often report dissatisfaction with the disclosure process due to insufficient information and support. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
55/100
There was a significantly higher risk of developing a dementia diagnosis in Hispanic/Latino and NHB participants than NHW participants and comparably increased dementia hazard ratios in the Hispanic/Latino, NHB, and NHW APOE4 carriers than non-carriers (hazard ratio [HR] [95% confidence interval {CI}] 1.54 [1.25-1.91], 1.25 [1.00-1.57], and 1.55 [1.40-1.72]). 5 key findings →
Design: longitudinal study Participants: 9,784 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This cohort study evaluates the prevalence of dementia diagnoses among US adults with autism spectrum disorder. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →